Navigation Links
Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
Date:10/29/2009

a 4-week dose titration period followed by 52 weeks of treatment. The study was a randomized, double-blind, placebo-controlled, 3-arm, prospective trial with patients randomized to receive once-a-day treatment with low-dose Qnexa, full-dose Qnexa or placebo. Patients were asked to follow a hypocaloric diet representing a 500-calorie/day deficit and advised to implement a simple lifestyle modification program.

CONQUER (OB-303) Study Overview

The CONQUER study included 2,487 overweight and obese patients (1,737 females and 750 males) with high blood pressure, high cholesterol or type 2 diabetes across 93 centers in the United States. The average baseline BMI of the study population was 36.6 kg/ m(2) and baseline weight was 227 pounds. Patients had a 4-week dose titration period followed by 52 weeks of treatment. The study was a randomized, double-blind, placebo-controlled, 3-arm, prospective trial with patients randomized to receive once-a-day treatment with mid-dose Qnexa, full-dose Qnexa or placebo. Patients were asked to follow a hypocaloric diet representing a 500-calorie/day deficit and advised to implement a simple lifestyle modification program.

About Qnexa

Qnexa (Q-NEX-uh) is an investigational drug being developed to address weight loss. Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low dose phentermine and topiramate, which is believed to address both appetite and satiety - the two main mechanisms that impact eating behavior - in one capsule. In phase 2 and 3 clinical data to date, Qnexa has demonstrated significant weight loss, glycemic control, and improvement in cardiovascular risk factors.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), h
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
10. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
11. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Armada Health Care (Armada), ... (GPO), is pleased to announce an agreement with ... host of innovative specialty pharmacy patient program offerings. ... therapy management services to specialty patients via Armada,s ... Aurora will use the OTM platform as ...
(Date:8/21/2014)... /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ... Board of Directors, enhancing executive oversight and strengthening ... leading licensed producer of medicinal cannabis in ... years, experience in producing and supplying government-regulated pharmaceutical-grade ... As previously announced in a ...
(Date:8/21/2014)... Pa. , Aug. 21, 2014   ... ), a specialty biopharmaceutical company, today announced positive ... of collagenase clostridium histolyticum (or CCH) for the ... as cellulite. In the Phase 2a trial, all ... and high (0.84mg)) showed an improvement in the ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
... (Nasdaq: DNDN ) today announced that the ... convertible senior notes due January 15, 2016 (the "Notes") ... to purchase an additional $80 million aggregate principal amount ... exercise of the overallotment option, resulted in net proceeds ...
... Hospira, Inc. (NYSE: HSP ), the ... Food and Drug Administration (FDA) approval of Topotecan Injection, ... in the United States. The medication is a generic ... more than $140 million. Hospira,s topotecan is indicated for ...
Cached Medicine Technology:Dendreon Announces Exercise and Closing of Overallotment Option 2Hospira Announces FDA Approval of Topotecan Injection 2
(Date:8/21/2014)... to be elicited by T-type calcium channels in ... regulate influxes of calcium. These channels enable thalamic ... the neurons to enter a hyper-excited state. , ... firing and absence seizures, the researchers conducted an ... gene targeting techniques to delete the T-type calcium ...
(Date:8/21/2014)... 2014 The "North ... Devices Market by Angioplasty Balloon (Plain/Old, ... OCT), IVC Filter (Retrievable), Endovascular Stent ... and studies the major market drivers, ... and Canada. , Browse 108 market ...
(Date:8/21/2014)... August 21, 2014 mynt welcomes industry ... promoters to join its growing company. Since its pre-launch ... in product sales and continues to gain momentum leading ... , Rob and Tiffanie came into network marketing by ... a number of network marketing companies. Tiffanie needed help ...
(Date:8/21/2014)... One of the emerging trends in the market ... This increases the availability and accessibility of these products to ... Ostomy Care Accessories market to grow at a ... the report, the Global Ostomy Care Accessories market is driven ... the major drivers. The number of procedures is increasing owing ...
(Date:8/21/2014)... Australian scientists say a commercially available ... been used to successfully fight mesothelioma in lab mice. ... new research. Click here to read it now. ... treated mesothelioma cells with the S. aureus ... while simultaneously stimulating a stronger anti-tumor response in healthy ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2Health News:Ostomy Care Accessories Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Ostomy Care Accessories Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Ostomy Care Accessories Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2
... is a primary long-term complication among premature infants suffering ... risk for pulmonary hypertension and impaired growth, and ... neurological problems. ,A new study finds premature ... with inhaled nitric oxide. ,Researchers from the University ...
... have lasted for less than three months. ,A new ... exercise sheet// handouts, and telephone follow-up calls may help ... ,Researchers from Indiana University developed a self-management program for ... focuses on boosting confidence in order to increase their ...
... a step forward in their search for a cure for ... the spleen appear to develop into insulin producing //pancreatic islet ... with diabetes. ,The latest research is a follow ... advanced type 1 diabetes in mice. The new research focuses ...
... New research shows screening newborns for biochemical genetic disorders ... parents. However, researchers say false-positive screening results may increase ... genetic disorders required a separate test, but now, doctors ... just one sample of blood by using a device ...
... transplanting chimpanzee organs into humans in need of an organ ... survived 20 days. // Since then, doctors have continued to ... cells to treat various diseases, all with varying degrees of ... -- also known as xenotransplantation. ,Dick Beyer ...
... Arthritis is a common health problem worldwide. Both osteoarthritis ... patients. There is no cure for arthritis and no ... new study could help lead doctors towards a drug ... the molecular pathway and an enzyme that play a ...
Cached Medicine News:Health News:Screening Newborns Questioned 2Health News:Animals Can give us a second chance at life 2
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile....
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
... Endotracheal Tube Kits (silicone) Magill, ... includes a SidePort™ AutoControl™ airway connector, ... mm ISO connector., ,The wire ... helping to ensure an open airway., ...
... Portex® Blue Line® uncuffed ... Magill or Murphy styles, in ... ,Blue Line® adult and pediatric ... from implant-tested polyvinyl chloride with ...
Medicine Products: